Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: A comprehensive evaluation

Nuclear Medicine Communications

Volumn 30, Issue 12, 2009, Pages 908-917

  Barwick, Tara ^a   Bencherif, Badreddine ^c   Mountz, James M ^c   Avril, Norbert ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

F 18 fluoro 3' deoxy 3' L fluorothymidine; Imaging; PET CT; Proliferation

Indexed keywords

3' FLUOROTHYMIDINE F 18; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CISPLATIN; CYTOSTATIC AGENT; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NUCLEOSIDE TRANSPORTER; THYMIDINE KINASE 1; ZIDOVUDINE;

B CELL LYMPHOMA; BRAIN TUMOR; CANCER DIAGNOSIS; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVITY; ESOPHAGUS CANCER; FIBROSARCOMA; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH;

BRAIN NEOPLASMS; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 73649086240     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32832ee93b     Document Type: Review

References (83)

1. Rubini JR, Cronkite EP, Bond VP, Fliedner TM. The metabolism and fate of tritiated thymidine in man. J Clin Invest 1960; 39:909-918.
2. Wells P, Gunn RN, Alison M, Steel C, Golding M, Ranicar AS, et al. Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 2002; 62:5698-5702.
3. Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, et al. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 1999; 59:615-621.
4. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39:1757-1762.
5. Christman D, Crawford EJ, Friedkin M,Wolf AP. Detection of DNA synthesis in intact organisms with positron-emitting (methyl- 11C)thymidine. Proc Natl Acad Sci 1972; 69:988-992.
6. Shields AF, Graham MM, Kozawa SM, Kozell LB, Link JM, Swenson ER, et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med 1992; 33:581-584.
7. Blasberg RG, Roelcke U, Weinreich R, Beattie B, von Ammon K, Yonekawa Y, et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res 2000; 60:624-635.
8. Gardelle O, Roelcke U, Vontobel P, Crompton NE, Guenther I, Blauenstein P, et al. [76Br]Bromodeoxyuridine PET in tumor-bearing animals. Nucl Med Biol 2001; 28:51-57.
9. Toyohara J, Hayashi A, Sato M, Gogami A, Tanaka H, Haraguchi K, et al. Development of radioiodinated nucleoside analogs for imaging tissue proliferation: Comparisons of six 5-iodonucleosides. Nucl Med Biol 2003; 30:687-696.
10. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-1336.
11. Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: Current status and opportunities. Eur J Nucl Med Mol Imaging 2004; 31:1659-1672.
12. Reske SN, Deisenhofer S. Is 30-deoxy-30-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose? Eur J Nucl Med Mol Imaging 2006; 33 (Suppl 13):38-43.
13. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 30-fluoro-30-deoxythymidine and 30-azido-30-deoxythymidine. Antimicrob Agents Chemother 1992; 36:808-818.
14. Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 1993; 33:235-252.
15. Seitz U, Wagner M, Neumaier B,Wawra E, Glatting G, Leder G, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 30-[(18)F]fluoro-30-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002; 29:1174-1181.
16. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995; 35:69-89.
17. Sherley JL, Kelly TJ. Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. J Biol Chem 1988; 263:375-382.
18. Grierson JR, Shields AF. Radiosynthesis of 30-deoxy-30-[(18)F] fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000; 27:143-156.
19. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 30-deoxy-30-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 2005; 46:371-380.
20. Shields AF, Briston DA, Chandupatla S, Douglas KA, Lawhorn-Crews J, Collins JM, et al. A simplified analysis of [18F]30-deoxy-30 -fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging 2005; 32:1269-1275.
21. Rasey JS, Grierson JR,Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43:1210-1217.
22. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, et al. In vivo validation of 30deoxy-30-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: Correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8:3315-3323.
23. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30:1407-1412.
24. Buck AK, Halter G, Schirrmeister H, Kotzerke J,Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003; 44:1426-1431.
25. Hartmann H, Vogt MW, Durno AG, Hirsch MS, Hunsmann G, Eckstein F. Enhanced in vitro inhibition of HIV-1 replication by 30-fluoro-30-deoxythymidine compared to several other nucleoside analogs. AIDS Res Hum Retroviruses 1988; 4:457-466.
26. Flexner C, van der HC, Jacobson MA, Powderly W, Duncanson F, Ganes D, et al. Relationship between plasma concentrations of 30-deoxy-30-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis 1994; 170:1394-1403.
27. Turcotte E, Wiens LW, Grierson JR, Peterson LM, Wener MH, Vesselle H. Toxicology evaluation of radiotracer doses of 30-deoxy-30- [18F]fluorothymidine (18F-FLT) for human PET imaging: laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med 2007; 7:3.
28. Spence AM, Muzi M, Link JM, Hoffman JM, Eary JF, Krohn KA. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies. Mol Imaging Biol 2008; 10:271-280.
29. Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 2003; 44:1482-1488.
30. Martin SJ, Eisenbarth JA, Wagner-Utermann U, Mier W, Henze M, Pritzkow H, et al. A new precursor for the radiosynthesis of [18F]FLT. Nucl Med Biol 2002; 29:263-273.
31. Yun M, Oh SJ, Ha HJ, Ryu JS, Moon DH. High radiochemical yield synthesis of 30-deoxy-30-[18F]fluorothymidine using (5-O-dimethoxytrityl-20- deoxy-30-O-nosyl-beta-D-threo pentofuranosyl)thymine and its 3-N-BOC-protected analogue as a labeling precursor. Nucl Med Biol 2003; 30:151-157.
32. Machulla HJ, Blocher A, Kuntzsch M, Piert M,Wei R, Grierson JR. Simplified labeling approach for synthesizing 30-deoxy-30-[F-18] flurothymidine [F-18]FLT. J Radioanal Nucl Chem 2000; 243:843-846.
33. Oh SJ, Mosdzianowski C, Chi DY, Kim JY, Kang SH, Ryu JS, et al. Fully automated synthesis system of 30-deoxy-30-[18F]fluorothymidine. Nucl Med Biol 2004; 31:803-809.
34. Teng B, Wang S, Fu Z, Dang Y, Wu Z, Liu L. Semiautomatic synthesis of 30-deoxy-30-[18F]fluorothymidine using three precursors. Appl Radiat Isot 2006; 64:187-193.
35. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 30-deoxy-30-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005; 46:274-282.
36. Muzi M, Spence AM, O'Sullivan F, Mankoff DA,Wells JM, Grierson JR, et al. Kinetic analysis of 30-deoxy-30-18F-fluorothymidine in patients with gliomas. J Nucl Med 2006; 47:1612-1621.
37. De Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, et al. Reproducibility of quantitative 18F-30-deoxy-30- fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 2009; 36:389-395.
38. Kenny L, Coombes RC, Vigushin DM, Al Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 30-deoxy-30 - [(18)F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007; 34:1339-1347.
39. Shields AF, Lawhorn-Crews JM, Briston DA, Zalzala S, Gadgeel S, Douglas KA, et al. Analysis and reproducibility of 30-Deoxy-30- [18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res 2008; 14:4463-4468.
40. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003; 44:2027-2032.
41. Toyohara J,Waki A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of FLT as a cell proliferation marker: Comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002; 29:281-287.
42. Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra SK, et al. The uptake of 30-deoxy-30-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005; 32:257-263.
43. Van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM,Wesseling J, Elsinga PH, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 2005; 46:400-404.
44. Yang YJ, Ryu JS, Kim SY, Oh SJ, Im KC, Lee H, et al. Use of 30-deoxy-30- [18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 2006; 33:412-419.
45. Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, et al. Evaluation of 30-deoxy-30-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004; 45:1754-1758.
46. Molthoff CF, Klabbers BM, Berkhof J, Felten JT, van Gelder M,Windhorst AD, et al. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: Comparison of 20-deoxy-20-[18F]fluoro-D-glucose (FDG) and 30-[18F]fluoro-30-deoxythymidine (FLT). Mol Imaging Biol 2007; 9:340-347.
47. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 30-deoxy-30-[18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005; 65:4202-4210.
48. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 30-deoxy-30-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63:3791-3798.
49. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002; 29:1462-1469.
50. Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [(18)F]FLT. Eur J Nucl Med Mol Imaging 2007; 34:1775-1782.
51. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 30-deoxy-30-18F-fluorothymidine PET. J Nucl Med 2005; 46:114-120.
52. Graf N, Herrmann K, den HJ, Fend F, Schuster T,Wester HJ, et al. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol 2008; 10:349-355.
53. Pan MH, Huang SC, Liao YP, Schaue D,Wang CC, Stout DB, et al. FLT-PET imaging of radiation responses in murine tumors. Mol Imaging Biol 2008; 10:325-334.
54. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39:1757-1762.
55. Buchmann I, Neumaier B, Schreckenberger M, Reske S. [18F]30-deoxy-30- fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations - a pilot study. Cancer Biother Radiopharm 2004; 19:436-442.
56. Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK, et al. Potential impact of [18F]30-deoxy-30-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30:988-994.
57. Been LB, Elsinga PH, de Vries J, Cobben DC, Jager PL, Hoekstra HJ, et al. Positron emission tomography in patients with breast cancer using (18)F-30-deoxy-30-fluoro-l-thymidine [(18)F-FLT]-a pilot study. Eur J Surg Oncol 2006; 32:39-43.
58. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med 2005; 46:945-952.
59. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005; 46:1948-1958.
60. Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M, et al. 30-[18F]fluoro-30-deoxythymidine [(18F)-FLT] as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res 2003; 63:2681-2687.
61. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004; 31:720-724.
62. Cobben DC, Elsinga PH, Suurmeijer AJ, Vaalburg W, Maas B, Jager PL, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-30 -fluoro-30-deoxy-L-thymidine. Clin Cancer Res 2004; 10:1685-1690.
63. Buck AK, Schirrmeister H, Hetzel M, Von Der HM, Halter G, Glatting G, et al. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331-3334.
64. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose- positron emission tomography. Chest 2006; 129:393-401.
65. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003; 52:1602-1606.
66. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006; 66:11055-11061.
67. Cobben DC, Elsinga PH, Hoekstra HJ, Suurmeijer AJ, Vaalburg W, Maas B, et al. Is 18F-30-fluoro-30-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med 2004; 45:1677-1682.
68. Buck AK, Hetzel M, Schirrmeister H, Halter G, Moller P, Kratochwil C, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005; 32:525-533.
69. Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 30-deoxy-30-18F-fluorothymidine and 18F-FDG. J Nucl Med 2008; 49:186-194.
70. Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma 2007; 48:746-753.
71. Cobben DC, van der Laan BF, Maas B, Vaalburg W, Suurmeijer AJ, Hoekstra HJ, et al. 18F-FLT PET for visualization of laryngeal cancer: Comparison with 18F-FDG PET. J Nucl Med 2004; 45:226-231.
72. Troost EG, Vogel WV, Merkx MA, Slootweg PJ, Marres HA, PeetersWJ, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007; 48:726-735.
73. Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, et al. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 2008; 35:2009-2017.
74. Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ, et al. [18F]30-deoxy-30-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005; 32:653-659.
75. Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. 18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging 2007; 34:1003-1011. (Pubitemid 46919556)
76. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, et al. Glioma proliferation as assessed by 30-fluoro-30-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 2008; 14:2049-2055.
77. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5:584-590.
78. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 30-[F-18]fluoro-30-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006; 8:36-42.
79. Herrmann K,Wieder HA, Buck AK, Schoffel M, Krause BJ, Fend F, et al. Early response assessment using 30-deoxy-30-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin0s lymphoma. Clin Cancer Res 2007; 13:3552-3558.
80. Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, et al. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008; 14:7423-7429.
81. Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, et al. PET imaging with [(18)F]30-deoxy-30-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007; 34:878-883.
82. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007; 20:4714-4721.
83. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008; 49 (Suppl 2):64S-80S.